Journal of Clinical Endocrinology & Metabolism, Vol 60, 34-36, Copyright © 1985 by Endocrine Society

ARTICLES

Progestins increase endogenous opioid peptide activity in postmenopausal women

RF Casper and S Alapin-Rubillovitz

To determine the effect of administration of a progestin alone on endogenous opioid peptide activity, we infused naloxone (2 mg/h for 4 h) into seven estrogen-deficient postmenopausal women before and after oral medroxyprogesterone acetate (Provera; 20 mg) daily for 30 days. Baseline serum LH levels were significantly decreased by the Provera therapy [70.3 +/- 6.6 (+/- SE) vs. 27.5 +/- 1.7 mIU/ml; P less than 0.001]. Naloxone infusion before Provera treatment had no effect on serum LH levels. In contrast, after Provera therapy, a significant (P less than 0.001) increase in LH levels toward the pre-Provera baseline occurred with naloxone infusion. These findings suggest that progestins exert their negative feedback effects on LH at least in part through an opioid peptide-mediated mechanism and that progestin treatment alone can reestablish opiatergic control of LH.

This article has been cited by other articles:

				R. L. Goodman, L. M. Coolen, G. M. Anderson, S. L. Hardy, M. Valent, J. M. Connors, M. E. Fitzgerald, and M. N. Lehman Evidence That Dynorphin Plays a Major Role in Mediating Progesterone Negative Feedback on Gonadotropin-Releasing Hormone Neurons in Sheep Endocrinology, June 1, 2004; 145(6): 2959 - 2967. [Abstract] [Full Text] [PDF]

				C. D. Foradori, L. M. Coolen, M. E. Fitzgerald, D. C. Skinner, R. L. Goodman, and M. N. Lehman Colocalization of Progesterone Receptors in Parvicellular Dynorphin Neurons of the Ovine Preoptic Area and Hypothalamus Endocrinology, November 1, 2002; 143(11): 4366 - 4374. [Abstract] [Full Text] [PDF]

				C. R. McCartney, M. B. Gingrich, Y. Hu, W. S. Evans, and J. C. Marshall Hypothalamic Regulation of Cyclic Ovulation: Evidence That the Increase in Gonadotropin-Releasing Hormone Pulse Frequency during the Follicular Phase Reflects the Gradual Loss of the Restraining Effects of Progesterone J. Clin. Endocrinol. Metab., May 1, 2002; 87(5): 2194 - 2200. [Abstract] [Full Text] [PDF]

				A. M. Paoletti, S. Floris, M. Mannias, M. Orrù, D. Crippa, R. Orlandi, M. Del Zompo, and G. B. Melis Evidence That Cyproterone Acetate Improves Psychological Symptoms and Enhances the Activity of the Dopaminergic System in Postmenopause J. Clin. Endocrinol. Metab., February 1, 2001; 86(2): 608 - 612. [Abstract] [Full Text]

				Y. R. Smith, J.-K. Zubieta, M. G. del Carmen, R. F. Dannals, H. T. Ravert, H. A. Zacur, and J. J. Frost Brain Opioid Receptor Measurements by Positron Emission Tomography in Normal Cycling Women: Relationship to Luteinizing Hormone Pulsatility and Gonadal Steroid Hormones J. Clin. Endocrinol. Metab., December 1, 1998; 83(12): 4498 - 4505. [Abstract] [Full Text]